Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The role of the bradykinin-generating system in the pathogenesis of cancer was explored by simultaneously measuring plasma prekallikrein (PK), the precursor of kallikrein, which is the major enzyme responsible for kinin generation, and plasma kininogens (KNG), which are precursors of kinin, in patients with various cancers. The mean value of plasma PK in healthy volunteers was 2.5 +/- 0.5 (mean +/- SD) units/mg plasma protein and that in cancer patients (all stage IV) was 1.7 +/- 0.7 units/mg plasma protein. The mean value of plasma KNG in healthy volunteers was 12.5 +/- 2.0 ng kinin equivalents/mg plasma protein and that in cancer patients was 10.9 +/- 2.8 ng. These data showed that plasma PK and plasma KNG values were significantly lower in cancer patients compared with healthy volunteers (P less than or equal to 0.005 for PK; 0.0005 less than P less than or equal to 0.005 for KNG; n = 28 for healthy subjects; n = 29 for cancer patients). These data appear to indicate that conversion of PK to kallikrein would probably occur with concomitant consumption of KNG by newly generated kallikrein for kinin generation in cancer patients. Early stage cancer patients showed little difference from healthy volunteers. For the in vitro study, activation of purified Hageman factor (HF) and PK was examined by using cancer cell lines and virus-transformed cells that produced plasminogen activator (PA) at a high rate. Both HF and PK were activated in the presence of plasminogen. Diploid cell lines and primary fibroblasts, which did not produce PA, activated neither HF nor PK. Taking all these data together, we conclude that kinin generation does occur in the plasma of patients with advanced cancer, and that one of the initiation mechanisms of the kinin-generating cascade appears to be mediated by plasmin and to depend on cancer cell-derived PA activity.
 ...
PMID:Kinin-generating cascade in advanced cancer patients and in vitro study. 190 58

In perfused rat hindlegs, platelet-activating factor and bradykinin induced the acute release of both tissue-type plasminogen activator (t-PA) and von Willebrand Factor (vWF). The time course of release was similar for both proteins, and the amounts of t-PA and vWF released under various conditions were closely correlated. Release of both t-PA and vWF required extracellular calcium, and could be induced by the calcium ionophore A-23187. Protein synthesis was not required for release to occur. Phorbol myristate acetate also induced release of t-PA and vWF, though with a different time course; DDAVP was inactive. The results suggest that the release of t-PA, and that of vWF, are closely linked at the cellular level.
 ...
PMID:The simultaneous acute release of tissue-type plasminogen activator and von Willebrand factor in the perfused rat hindleg region. 211 27

The acute release of tissue-type plasminogen activator (t-PA) was studied in perfused rat hindlegs. Pretreatment of rats with the protein syNthesis inhibitor cycloheximide (2 mg/kg) at 1, 3 or 5 h prior to perfusion of rat hindlegs did not influence the amount of t-PA released by platelet-activating factor (20 nM) or bradykinin (1 microM). The amount of t-PA activity that could be extracted from hindleg skeletal muscle was not decreased by cycloheximide pretreatment though it was decreased in lung extracts. The in vivo release of t-PA was not affected by cycloheximide pretreatment. The data suggest that the acute release of t-PA from vascular endothelial cells does not require ongoing protein synthesis, but that acutely released t-PA is derived from a stable endothelial storage pool.
 ...
PMID:Protein synthesis inhibition by cycloheximide does not affect the acute release of tissue-type plasminogen activator. 250 56

The kaolin-induced activation of factor XII (XII) to XIIa was studied in plasminogen-free human citrated plasma treated with acetone in the presence of benzamidine 7.5 mM. XIIa was assayed as prekallikrein (PK) activator. The significance of the concentrations of XII, PK and high molecular weight kininogen (HMrK) was examined using mixtures of normal plasma and plasma genetically deficient in these factors. At the high plasma dilution used (1 + 23 v/v in the kaolin incubate) a joint estimation of the factors was obtained. A reduction in amount of XII, PK or HMrK resulted in a correspondingly reduced yield of XIIa. Plasma kallikrein present was assayed as S-2302 amidase. The concentration of PK in XII-deficient plasma was normal, in HMrK-deficient plasma about 30% of normal. The activation of XII was studied in fresh plasma as well as in plasma stored for 3-6 months at -70 degrees, and the activation with acetone was carried out in the presence and in the absence of benzamidine, EDTA or purified HMrK. In previous work benzamidine was found to protect the cofactor function of purified HMrK in the assay system used, and EDTA was found to inhibit purified human plasma kallikrein assayed as plasminogen activator. The present results support the previous observations, and indicate that acetone treatment of fresh human plasma (benzamidine present) results in the activation of plasma kallikrein in a functional state that requires kinin-free, but otherwise native HMrK as a cofactor for the activation of XII.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Activation of factor XII in acetone-treated human plasma: significance of the functional state of plasma kallikrein for the extent of activation. 349 Jul 38

We have purified and characterized the major N-benzoyl-L-arginine ethyl ester hydrolase from the venom of Heloderma horridum horridum. The enzyme belongs to the serine proteinase family, and its activity vs. peptide amide substrates and human high-molecular-weight kininogen suggests a similarity to the family of kallikreins. This interpretation is corroborated by its reactivity with the natural inhibitors soybean trypsin inhibitor and Kunitz-type bovine pancreatic trypsin inhibitor (aprotinin). Injection of the enzyme (2-16 micrograms/kg) into anesthetized rabbits leads to a rapid dose-dependent transient decrease of the arterial blood pressure. Like glandular kallikrein it specifically converts single-chain tissue type plasminogen activator into its double chain form. In contrast to other kallikrein-like enzymes from snake venoms it shows no thrombin-like or plasminogen activator activity. The enzyme is a single-chain glycoprotein (Mr 63,000). The N-terminal sequence revealed significant homology to pig pancreatic kallikrein and to kallikrein like enzymes from Crotalus atrox and Crotalus adamanteus venom. This enzyme, which we name Helodermatine, is the first purified from Sauria with kallikrein-like properties.
 ...
PMID:Helodermatine, a kallikrein-like, hypotensive enzyme from the venom of Heloderma horridum horridum (Mexican beaded lizard). 353 91

The prolonged partial thromboplastin time observed in the plasma of a 36 year old asymptomatic man was related to the reduced prekallikrein activities (coagulant; antigenic; and amidolytic) and the absence of coagulant and immunologic activities of high molecular weight kininogen (HMWKg). The patient's plasma also exhibited impaired surface-mediated fibrinolysis and impaired generation of kallikrein. The coagulation defect was identified as the "Fitzgerald trait". The levels of CH50, C2, C4 and C-1 inactivator were normal. Venous occlusion in the patient gave rise to a normal release of extrinsic plasminogen activator from the vascular endothelium. The administration of DDAVP led to a FVIII/VWF response which was similar to that obtained in healthy subjects. No alteration could be observed in the contact phase proteins after DDAVP administration.
 ...
PMID:New congenital deficiency of high molecular weight kininogen and prekallikrein (Fitzgerald trait). Study of response to DDAVP and venous occlusion. 363 67

Kinetics of plasminogen activation by purified activated plasma kallikrein have been studied in a purified system using Glu-plasminogen as a substrate. A synthetic paranitroanilide substrate was used for quantification of the formed plasmin. In that system kallikrein cleaved plasminogen with a Km value of 0.56 microM, a kcat of 1.6 X 10(-4) s-1 and a catalytic efficiency kcat/Km of 2.7 X 10(-4) s-1 microM-1. Addition of CNBr fibrinogen fragments resulted in an increase of Km to 1.18 microM, an increase of kcat to 5.1 X 10(-4) s-1 and an increase in the catalytic rate constant kcat/Km to 4.3 X 10(-4) s-1 microM-1. Addition of purified high molecular weight kininogen had no effect on the kinetics of plasminogen activation whether or not stimulating fibrinogen fragments were present. A stimulating effect of fibrinogen fragments could also be shown for the cleavage of the low molecular weight paranitroanilide substrate H-D-Pro-Phe-Arg-pNA by kallikrein; in that system the kcat for substrate cleavage by kallikrein increased from 200 s-1 to 280 s-1, while the Km value remained unchanged. From these data it can be concluded that based on enzyme kinetic studies plasminogen activator activity of purified plasma kallikrein is about 1/1000 of that of high molecular weight urokinase and is only slightly influenced by addition of stimulating fibrinogen fragments. Addition of high molecular weight kininogen does not affect plasminogen activator activity of purified plasma kallikrein.
 ...
PMID:Kinetic analysis of plasminogen activation by purified plasma kallikrein. 385 Jun 47

Release of tissue plasminogen activator into the circulation of rats in response to intravascular injections of vasoactive agents is studied by using a sensitive and specific clot lysis assay. Intra-arterial bradykinin elicits a rapid and transient rise in circulating plasminogen activator, which is maximum within one minute and is cleared within four to eight minutes. The plasminogen activator is fibrin dependent and is neutralized by an antiserum to human tissue-type plasminogen activator. Bradykinin is 1,000-fold more potent than the other agonists tested, which include histamine, norepinephrine, epinephrine, eledoisin-related peptide, arginine-vasopressin, lysine-vasopressin, desmopressin acetate, carbachol, and acetylcholine. Potency of bradykinin is related to its amino acid sequence. Sequential infusions of bradykinin produce a tachyphylactoid response that could be overcome by increasing the dose of the sequential bradykinin challenge. It is concluded that the characteristics of the responses to bradykinin and other agents in vivo differ significantly from those observed in isolated tissue preparations.
 ...
PMID:Tissue plasminogen activator release in vivo in response to vasoactive agents. 392 59

1. Cellulose sulphate, a kinin-releasing agent, produced fibrinolytic activity in plasma when administered intravenously to the rat but not when added to fresh rat plasma in vitro. The in vivo effect was maximal within 1 min and disappeared within 10-20 minutes. It was retained in plasma taken 1 min after the injection and kept at room temperature for 30 minutes.2. A decrease of anti-fibrinolytic potency measured against urokinase-activated bovine plasmin, was shown to occur in plasma of rats given cellulose sulphate.3. Activated rat plasma lysed heat-denatured fibrin: it probably contains free plasmin as well as plasminogen activator.4. Adrenalectomized rats did not exhibit fibrinolytic activity nor statistically significant benzoyl-arginine ethyl ester-esterase activation in plasma after cellulose sulphate treatment.5. Adrenalectomized rats had significantly increased levels of plasma kininogen, but were normally sensitive to the kininogen-depleting action of cellulose sulphate.6. The increased plasma kininogen of adrenalectomized rats seems to be a consequence of the impairment of the plasminogen activating mechanism.
 ...
PMID:Fibrinolytic activity evoked in the plasma of the normal and adrenalectomized rat by cellulose sulphate. 507 29

In a previous study of plasma specimens from reactors to clinical dextran, it was concluded that a factor activated by acetone converted the high-molecular-weight kininogen (HMrK) into a non-functional state. We recently identified the HMrK-destroying factor as a plasma kallikrein modification with high plasminogen activator (PGA) activity. The aim of the present work was to investigate whether the level of plasma kallikrein, assayed as PGA on fibrin plates, was higher than normal in plasma from patients reacting to dextran or radiographic contrast media. Plasma specimens from 10 reactors and 16 controls were examined. No difference in PGA level could be detected between reactors and controls in citrated plasma stabilized with benzamidine 9 mM, whereas a significant loss of PGA activity took place in citrated reactor plasma during the acetone activation procedure. The loss of PGA activity could not be due to known inhibitors of plasma kallikrein. It was only partial, and did not influence the amidase effect against the tripeptide substrate H-D-Pro-Phe-Arg-pNA. The results might indicate the presence in plasma of different amounts of an unknown constituent important for the obtainable level of plasma kallikrein with high PGA activity. The significant loss of PGA activity in reactor plasma might indicate an abnormally high level of the unknown plasma factor.
 ...
PMID:Assay of prekallikrein as plasminogen proactivator in plasma specimens from reactors to dextran or to contrast media. 608 73


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>